Post-Stroke Medication Relay (REMEDIPA)

Prior to discharge from hospital and return home, patients managed for ischemic stroke will receive a pharmaceutical interview to discuss their discharge prescription (indication, method of administration, precautions, and possible side effects).

Improvements in the use of medications in the community and in hospital follow-up.

Telephone interviews or teleconsultations will make it possible to assess the patient's knowledge of his or her treatment and to re-explain it if necessary to improve patient compliance with treatment.

Study Overview

• Status: Completed
• Conditions: Stroke, Ischemic; Medication Compliance
• Intervention / Treatment: Other: Questionnaire

• Study Type: Observational
• Enrollment (Actual): 54

Contacts and Locations

Study Locations

• France
  • Bron, France, 69677
    • Service de Neurologie Vasculaire, Unité 201 Hôpital Neurologique Pierre Wertheimer, HCL

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adults patients managed in stroke unit following ischemic stroke who benefiting from a direct return at home.

Description

Inclusion Criteria:

• Adult patients managed in stroke unit following ischemic stroke
• Benefiting from a direct return home
• Non-opposition to participation

Exclusion Criteria:

- None

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke	The value of a telephone interview / teleconsultation will be assess by comparison of treatment knowledge between the first questionnaire at one week and the second questionnaire at two months after the pharmaceutical interview and hospital discharge. Statistical evaluation by comparative tests at one week versus two months. Assessment will focus on treatment knowledge (score between 0 and 3), adherence (score between 0 and 6) and adverse events (score between 0 and 3)	1 week
Assess the value of a telephone interview / teleconsultation after discharge from hospital following an ischemic stroke	The value of a telephone interview / teleconsultation will be assess by comparison of treatment knowledge between the first questionnaire at one week and the second questionnaire at two months after the pharmaceutical interview and hospital discharge. Statistical evaluation by comparative tests at one week versus two months. Assessment will focus on treatment knowledge (score between 0 and 3), adherence (score between 0 and 6) and adverse events (score between 0 and 3)	2 months

Collaborators and Investigators

• Sponsor: Hospices Civils de Lyon

Study record dates

Study Major Dates

• Study Start (Actual): March 11, 2021
• Primary Completion (Actual): April 27, 2022
• Study Completion (Actual): April 27, 2022

Study Registration Dates

• First Submitted: January 4, 2021
• First Submitted That Met QC Criteria: January 5, 2021
• First Posted (Actual): January 6, 2021

Study Record Updates

• Last Update Posted (Actual): March 18, 2026
• Last Update Submitted That Met QC Criteria: March 16, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Stroke; Behavior; Treatment Adherence and Compliance; Health Behavior; Patient Compliance; Patient Acceptance of Health Care; Ischemic Stroke; Medication Adherence; Health Care Quality, Access, and Evaluation; Investigative Techniques; Epidemiologic Methods; Data Collection; Health Care Evaluation Mechanisms; Quality of Health Care; Public Health; Environment and Public Health; Surveys and Questionnaires
• Other Study ID Numbers: 69HCL20_0713

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No